Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.47 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.42 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.42 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.42 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880871 | 0.92 | PDE5A (0.52) | PDE5A | |
| SCHEMBL2883894 | 0.90 | PDE5A (0.45) | PDE5AGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL2883500 | 0.89 | PDE5A (0.42) | PDE5A | |
| SCHEMBL2883492 | 0.85 | PDE5A (0.42) | PDE5AGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL2883555 | 0.85 | PDE5A (0.42) | PDE5A | |
| SCHEMBL2885436 | 0.84 | PDE5A (0.42) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL2881292 | 0.82 | MAPT (0.48) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL2885583 | 0.80 | PDE5A (0.48) | PDE5A | |
| SCHEMBL2888185 | 0.78 | PDE5A (0.44) | PDE5A | |
| SCHEMBL21787278 | 0.77 | PDE5A (0.49) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| EP-2013205-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | Bayer HealthCare AG (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | AADAC, CYP11B2, PC | PDE5A 984/4885GUCY1B2 2430/4885GUCY1A2 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.